550 related articles for article (PubMed ID: 8540495)
1. Prognosis assessment of cirrhotic patients with refractory ascites treated with a peritoneovenous shunt.
Guardiola J; Xiol X; Escribá JM; Castellví JM; Castellote J; Baliellas C; Rafecas A; Casais LA
Am J Gastroenterol; 1995 Dec; 90(12):2097-102. PubMed ID: 8540495
[TBL] [Abstract][Full Text] [Related]
2. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
[TBL] [Abstract][Full Text] [Related]
3. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites.
Guardiola J; Baliellas C; Xiol X; Fernandez Esparrach G; Ginès P; Ventura P; Vazquez S
Am J Gastroenterol; 2002 Sep; 97(9):2374-8. PubMed ID: 12358259
[TBL] [Abstract][Full Text] [Related]
4. [MELD score in prediction of early mortality in patients suffering refractory ascites treated by TIPS].
Fejfar T; Safka V; Hůlek P; Vanásek T; Krajina A; Jirkovský V
Vnitr Lek; 2006 Sep; 52(9):771-6. PubMed ID: 17091599
[TBL] [Abstract][Full Text] [Related]
5. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites.
Ginès P; Arroyo V; Vargas V; Planas R; Casafont F; Panés J; Hoyos M; Viladomiu L; Rimola A; Morillas R
N Engl J Med; 1991 Sep; 325(12):829-35. PubMed ID: 1875966
[TBL] [Abstract][Full Text] [Related]
6. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients.
Salerno F; Borroni G; Moser P; Badalamenti S; Cassarà L; Maggi A; Fusini M; Cesana B
Am J Gastroenterol; 1993 Apr; 88(4):514-9. PubMed ID: 8470631
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites.
Moreau R; Delègue P; Pessione F; Hillaire S; Durand F; Lebrec D; Valla DC
Liver Int; 2004 Oct; 24(5):457-64. PubMed ID: 15482343
[TBL] [Abstract][Full Text] [Related]
8. [Comparative evaluation of the effects of a peritoneo-venous shunt and of concentration-reinfusion on the survival of cirrhotic subjects with "intractable" ascites].
Torre GC; Testa R
Minerva Med; 1982 Jun; 73(27):1871-5. PubMed ID: 7088400
[TBL] [Abstract][Full Text] [Related]
9. [Peritoneovenous shunting in intractable ascites of cirrhosis. Results of a prospective study on improving prognostic factors].
Hillaire S; Labianca M; Smadja C; Grange D; Franco D
Gastroenterol Clin Biol; 1988 Oct; 12(10):681-6. PubMed ID: 3220223
[TBL] [Abstract][Full Text] [Related]
10. Peritoneovenous shunting for cirrhotic versus malignant ascites.
Kostroff KM; Ross DW; Davis JM
Surg Gynecol Obstet; 1985 Sep; 161(3):204-8. PubMed ID: 2412302
[TBL] [Abstract][Full Text] [Related]
11. Poor outcome from peritoneovenous shunts for refractory ascites.
Scholz DG; Nagorney DM; Lindor KD
Am J Gastroenterol; 1989 May; 84(5):540-3. PubMed ID: 2719011
[TBL] [Abstract][Full Text] [Related]
12. Peritoneovenous shunting of intractable ascites in patients with cirrhosis: improving results and predictive factors of failure.
Hillaire S; Labianca M; Borgonovo G; Smadja C; Grange D; Franco D
Surgery; 1993 Apr; 113(4):373-9. PubMed ID: 8456392
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in patients with refractory ascites treated by transjugular intrahepatic porto-systemic shunt: From the liver to the kidney.
Hamel B; Guillaud O; Roman S; Vallin M; Pilleul F; Valette PJ; Henry L; Guibal A; Mion F; Dumortier J
Dig Liver Dis; 2014 Nov; 46(11):1001-7. PubMed ID: 25096966
[TBL] [Abstract][Full Text] [Related]
14. Natural history of patients hospitalized for management of cirrhotic ascites.
Planas R; Montoliu S; Ballesté B; Rivera M; Miquel M; Masnou H; Galeras JA; Giménez MD; Santos J; Cirera I; Morillas RM; Coll S; Solà R
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1385-94. PubMed ID: 17081806
[TBL] [Abstract][Full Text] [Related]
15. [Role of surgery in the treatment of refractory ascites in cirrhotic patients].
Borie DC; Vaillant JC; Breton S; Hannoun L
Ann Chir; 1999; 53(10):966-72. PubMed ID: 10670142
[TBL] [Abstract][Full Text] [Related]
16. Experimental, clinical, and metabolic results of side-to-side portacaval shunt for intractable cirrhotic ascites.
Orloff MJ; Orloff MS; Orloff SL; Girard B
J Am Coll Surg; 1997 Jun; 184(6):557-70. PubMed ID: 9179111
[TBL] [Abstract][Full Text] [Related]
17. Patient selection and survival after peritoneovenous shunting for nonmalignant ascites.
Smith RE; Nostrant TT; Eckhauser FE; Wilson JP; Knol JA; Strodel WE
Am J Gastroenterol; 1984 Aug; 79(8):659-62. PubMed ID: 6465114
[TBL] [Abstract][Full Text] [Related]
18. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.
Malinchoc M; Kamath PS; Gordon FD; Peine CJ; Rank J; ter Borg PC
Hepatology; 2000 Apr; 31(4):864-71. PubMed ID: 10733541
[TBL] [Abstract][Full Text] [Related]
19. [12-year experience with continuous peritoneovenous shunt in the treatment of therapy-resistant ascites and hepatorenal failure: benefits and pitfalls].
Kreuzer W
Wien Klin Wochenschr; 1989 Jan; 101(2):87-91. PubMed ID: 2916345
[TBL] [Abstract][Full Text] [Related]
20. [Long-term results of the peritoneovenous shunt in the treatment of intractable ascites in cirrhotic patients].
Dellepiane M; Capussotti L; Polastri R; Mensa G; Marucci MM; Fusario F
Minerva Med; 1987 May; 78(10):717-20. PubMed ID: 3587721
[No Abstract] [Full Text] [Related]
[Next] [New Search]
